Saturday 17 October 2026
Export EDSA’s income statement to Excel — free account
Edesa Biotech, Inc.
EDSA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.57
0.10
−3.75%
Follow EDSA
Edesa Biotech, Inc. (EDSA) P/E ratio
Edesa Biotech, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,772× (September 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Mar 2020 | 0.0× | — |
| Dec 2019 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,772×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LBPS 4D pharma PLC Sponsored ADR compare | n/m |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| CRVO CervoMed Inc. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| LITS Lite Strategy, Inc. compare | n/m |
| FLNA Cassava Sciences, Inc. compare | n/m |
| EDSA Edesa Biotech, Inc. | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)